A Phase 2 interventional study of rituximab [MabThera/Rituxan] and fludarabine in Lymphocytic Leukemia, Chronic, sponsored by Hoffmann-La Roche. Completed at 8 sites in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-18.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 197 studies testing rituximab in Leukemia, Lymphocytic, Chronic, B-Cell — 3 open to participants now, 12 under way, 4 of them phase 3. Rituximab · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 197 studies testing rituximab in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 87th largest by enrollment of the 189 interventional ones that give a count, is one of 20 that started in 2005, is one of 119 in phase 2, and was the 168th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →3 of the 197 studies testing rituximab in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:
Paolo Caimi, MD · Sites in United States
Ages 18+
BeOne Medicines · Sites in United States, Argentina, Australia and 18 more countries
Ages 18+
Paolo Ghia · Sites in Italy
Ages 18–65
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
197 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 56 · Phase 2 138 · Phase 3 18 · Phase 4 2
First in 1997; this study’s year is marked. 20 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 43 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 39 across the 189 interventional studies. Of the 166 that completed or were terminated, 93 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 197 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
48 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Hoffmann-La Roche: 1 open now, 2 under way, none of them phase 3. Of 46 finished, 28 (61%) have results posted.
Among the 48 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Hoffmann-La Roche, this one is the 28th largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2005, is one of 13 in phase 2, and was the 32nd registered.
Hoffmann-La Roche’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2003.
2 of the studies testing rituximab in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03467867Georgetown UniversityA Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL | 2026-12 |
| NCT04458610M.D. Anderson Cancer CenterZanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | 2027-05-26 |
Add all 2 to your calendar (.ics) → With an account.
Among the 197 studies testing rituximab in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among Hoffmann-La Roche’s 48 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of intense combination treatment including MabThera/Rituxan (rituximab), followed by MabThera/Rituxan maintenance therapy in patients with B-cell CLL who are naive to chemotherapy. The anticipated time on study treatment is 2.5 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: rituximab [MabThera/Rituxan] · Drug: fludarabine · Drug: cyclophosphamide
Drug page: Rituximab
Every 4 weeks for 6 cycles of induction, followed by maintenance therapy every 3 months x 8
Every 4 weeks, 6 cycles
Every 4 weeks, 3 cycles
Percentage of Participants With a Best Clinical Response of Clinical Remission (CR)
Best clinical response was determined according to the National Cancer Institute (NCI) Clinical and Clinical plus (+) Radiological evaluations by central response assessment. Assessment of response was performed according to the NCI revised guidelines for the diagnosis and treatment of chronic lymphocytic lymphoma (CLL) with additional computerized tomography (CT) scan evaluation of lymphadenopathy. Per NCI guidelines, CR requires all of the following criteria at least 2 months after the last treatment: no lymphadenopathy (Ly)/ hepatomegaly/ splenomegaly/constitutional symptoms; neutrophils greater than (\>)1500 per microliter (/µL), platelets (PL) \>100,000/µL, hemoglobin (Hb) \>11.0 grams per deciliter (g/dL), lymphocytes (LC) (less than) \<4000/µL, bone marrow (BM) sample must be normocellular for age, \<30% LC.
Time frame: Weeks 1, 5, 9, 12, 13, 17, 21 and 24
Percentage of Participants With the Best Clinical Response by Visit (Clinical Assessment)
Best clinical response was determined according to the NCI clinical evaluation and through radiological assessment. CR, CRi, CRu, partial remission (PR), partial remission with toxicity associated (PRTox), progressive disease (PD), and stable disease (SD) were evaluated. Assessment of response was performed according to the NCI revised guidelines for the diagnosis and treatment of CLL with additional CT scan evaluation of lymphadenopathy during the treatment period (Radiological). Response assessment for interim (Week 12), end of induction (Week 24) and at Final Staging (4 weeks after last maintenance dose). Last observation carried forward (LOCF) method was used for missing data. Percentages are based on the number of nonmissing observations within each stratum.
Time frame: Weeks 12 and 24 and at Final Staging (Week 4 after last maintenance dose)
Percentage of Participants With the Best Clinical Response by Visit (Clinical + Radiological Assessment)
Best clinical response was determined according to the NCI clinical evaluation and through radiological assessment. CR, CRi, CRu, PR, PRTox, PD, and SD were evaluated. Assessment of response was performed according to the NCI revised guidelines for the diagnosis and treatment of CLL with additional CT scan evaluation of lymphadenopathy during the treatment period (Radiological). Response assessment for interim (Week 12), end of induction (Week 24) and at Final Staging (4 weeks after last maintenance dose). LOCF method was used for missing data. Percentages are based on the number of nonmissing observations within each stratum.
Time frame: Weeks 12 and 24 and at Final Staging (Week 4 after last maintenance dose)
Time to Next Treatment - Percentage of Participants With an Event
Time to next treatment was calculated as the number of days from either discontinuation of the study drug or the administration of the last dose, until the participants needed next treatment.
Time frame: Weeks 1, 5, 9, 12, 13, 17, 21 and 24 and every 8 weeks for 64 Weeks and every 6 months
Time to Next Treatment - Time to Event
Time to next treatment was calculated as the number of days from either discontinuation of the study drug or the administration of the last dose, until the participants needed next treatment.
Time frame: Weeks 1, 5, 9, 12, 13, 17, 21 and 24 and every 8 weeks for 64 Weeks and every 6 months
Percentage of Participants With Adverse Events (AEs)
AEs were recorded from the date of first medication administration until 28 days after the last trial medication.
Time frame: Day 1 of Cycles 1, 2, 3, 4, 5, and 6 to 28 days after the last trial medication.
| Milestone | Rituximab, Fludarabine, Cyclophosphamide |
|---|---|
| Started | 43 |
| Completed | 16 |
| Not completed | 27 |
| Withdrew: Adverse event | 12 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Death | 2 |
| Withdrew: Other | 9 |
Best clinical response was determined according to the National Cancer Institute (NCI) Clinical and Clinical plus (+) Radiological evaluations by central response assessment. Assessment of response was performed according to the NCI revised guidelines for the diagnosis and treatment of chronic lymphocytic lymphoma (CLL) with additional computerized tomography (CT) scan evaluation of lymphadenopathy. Per NCI guidelines, CR requires all of the following criteria at least 2 months after the last treatment: no lymphadenopathy (Ly)/ hepatomegaly/ splenomegaly/constitutional symptoms; neutrophils greater than (\>)1500 per microliter (/µL), platelets (PL) \>100,000/µL, hemoglobin (Hb) \>11.0 grams per deciliter (g/dL), lymphocytes (LC) (less than) \<4000/µL, bone marrow (BM) sample must be normocellular for age, \<30% LC.
| percentage of participants | Rituximab, Fludarabine, Cyclophosphamide |
|---|---|
| NCI Clinical | 73.7 (56.9 to 86.6) |
| NCI Clinical (including CRu, CRi) | 94.7 (82.3 to 99.4) |
| NCI Clinical + Radiological | 63.2 (46.0 to 78.2) |
| NCI Clinical + Radiological (including CRu, CRi) | 78.9 (62.7 to 90.4) |
Best clinical response was determined according to the NCI clinical evaluation and through radiological assessment. CR, CRi, CRu, partial remission (PR), partial remission with toxicity associated (PRTox), progressive disease (PD), and stable disease (SD) were evaluated. Assessment of response was performed according to the NCI revised guidelines for the diagnosis and treatment of CLL with additional CT scan evaluation of lymphadenopathy during the treatment period (Radiological). Response assessment for interim (Week 12), end of induction (Week 24) and at Final Staging (4 weeks after last maintenance dose). Last observation carried forward (LOCF) method was used for missing data. Percentages are based on the number of nonmissing observations within each stratum.
| percentage of participants | Rituximab, Fludarabine, Cyclophosphamide |
|---|---|
| CR, Week 12 | 41.9 (27.0 to 57.9) |
| CRu, Week 12 | 16.3 (6.8 to 30.7) |
| CRi, Week 12 | 16.3 (6.8 to 30.7) |
| PR, Week 12 | 11.6 (3.9 to 25.1) |
| PRTox, Week 12 | 2.3 (0.1 to 12.3) |
| SD, Week 12 | 0.0 (0.0 to 8.2) |
| PD, Week 12 | 0.0 (0.0 to 8.2) |
| Not evaluable, Week 12 | 11.6 (3.9 to 25.1) |
| CR, Week 24 | 30.2 (17.2 to 46.1) |
| CRu, Week 24 | 11.6 (3.9 to 25.1) |
| CRi, Week 24 | 37.2 (23.0 to 53.3) |
| PR, Week 24 | 9.3 (2.6 to 22.1) |
| PRTox, Week 24 | 0.0 (0.0 to 8.2) |
| SD, Week 24 | 0.0 (0.0 to 8.2) |
| PD, Week 24 | 0.0 (0.0 to 8.2) |
| Not evaluable, Week 24 | 11.6 (3.9 to 25.1) |
| CR, Final staging | 60.5 (44.4 to 75.0) |
| CRu, Final staging | 7.0 (1.5 to 19.1) |
| CRi, Final staging | 11.6 (3.9 to 25.1) |
| PR, Final staging | 7.0 (1.5 to 19.1) |
| PRTox, Final staging | 0.0 (0.0 to 8.2) |
| SD, Final staging | 0.0 (0.0 to 8.2) |
| PD, Final staging | 2.3 (0.1 to 12.3) |
| Not evaluable, Final staging | 11.6 (3.9 to 25.1) |
Best clinical response was determined according to the NCI clinical evaluation and through radiological assessment. CR, CRi, CRu, PR, PRTox, PD, and SD were evaluated. Assessment of response was performed according to the NCI revised guidelines for the diagnosis and treatment of CLL with additional CT scan evaluation of lymphadenopathy during the treatment period (Radiological). Response assessment for interim (Week 12), end of induction (Week 24) and at Final Staging (4 weeks after last maintenance dose). LOCF method was used for missing data. Percentages are based on the number of nonmissing observations within each stratum.
| percentage of participants | Rituximab, Fludarabine, Cyclophosphamide |
|---|---|
| CR, Week 12 | 30.2 (17.2 to 46.1) |
| CRu, Week 12 | 4.7 (0.6 to 15.8) |
| CRi, Week 12 | 7.0 (1.5 to 19.1) |
| PR, Week 12 | 30.2 (17.2 to 46.1) |
| PRTox, Week 12 | 9.3 (2.6 to 22.1) |
| SD, Week 124 | 7.0 (1.5 to 19.1) |
| PD, Week 12 | 0.0 (0.0 to 8.2) |
| Not evaluable, Week 12 | 11.6 (3.9 to 25.1) |
| CR, Week 24 | 23.3 (11.8 to 38.6) |
| CRu, Week 24 | 7.0 (1.5 to 19.1) |
| CRi, Week 24 | 30.2 (17.2 to 46.1) |
| PR, Week 24 | 14.0 (5.3 to 27.9) |
| PRTox, Week 24 | 7.0 (1.5 to 19.1) |
| SD, Week 24 | 7.0 (1.5 to 19.1) |
| PD, Week 24 | 0.0 (0.0 to 8.2) |
| Not evaluable, Week 24 | 11.6 (3.9 to 25.1) |
| CR, Final staging | 48.8 (33.3 to 64.5) |
| CRu, Final staging | 7.0 (1.5 to 19.1) |
| CRi, Final staging | 7.0 (1.5 to 19.1) |
| PR, Final staging | 11.6 (3.9 to 25.1) |
| PRTox, Final staging | 2.3 (0.1 to 12.3) |
| SD, Final staging | 2.3 (0.1 to 12.3) |
| PD, Final staging | 9.3 (2.6 to 22.1) |
| Not evaluable, Final staging | 11.6 (3.9 to 25.1) |
Time to next treatment was calculated as the number of days from either discontinuation of the study drug or the administration of the last dose, until the participants needed next treatment.
| percentage of participants | Rituximab, Fludarabine, Cyclophosphamide |
|---|---|
| Time to Next Treatment - Percentage of Participants With an Event | 37.2 |
Time to next treatment was calculated as the number of days from either discontinuation of the study drug or the administration of the last dose, until the participants needed next treatment.
| days | Rituximab, Fludarabine, Cyclophosphamide |
|---|---|
| Time to Next Treatment - Time to Event | 423.3 ± 398.5 |
AEs were recorded from the date of first medication administration until 28 days after the last trial medication.
| percentage of participants | Rituximab, Fludarabine, Cyclophosphamide |
|---|---|
| Any AE | 100 |
| Related AE | 93.0 |
| Severe AE | 76.7 |
| SAE | 62.8 |
| Pregnancy | 0.0 |
Collected over Adverse events (AEs) were recorded from the date of first medication administration until 28 days after the last trial medication.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab, Fludarabine, Cyclophosphamide | — | 30/43 (69.8%) | 36/43 (83.7%) |
| Event | Rituximab, Fludarabine, Cyclophosphamide |
|---|---|
| PyrexiaGeneral disorders | 5/43 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/43 |
| PneumoniaInfections and infestations | 2/43 |
| Chest painGeneral disorders | 2/43 |
| LeukopeniaBlood and lymphatic system disorders | 2/43 |
| BronchitisInfections and infestations | 1/43 |
| Cytomegalovirus infectionInfections and infestations | 1/43 |
| PharyngitisInfections and infestations | 1/43 |
| Pneumonia primary atypicalInfections and infestations | 1/43 |
| Postoperative infectionInfections and infestations | 1/43 |
| Event | Rituximab, Fludarabine, Cyclophosphamide |
|---|---|
| NeutropeniaBlood and lymphatic system disorders | 23/43 |
| LeukopeniaBlood and lymphatic system disorders | 20/43 |
| ThrombocytopeniaBlood and lymphatic system disorders | 18/43 |
| LymphopeniaBlood and lymphatic system disorders | 14/43 |
| NauseaGastrointestinal disorders | 14/43 |
| CoughRespiratory, thoracic and mediastinal disorders | 14/43 |
| AnaemiaBlood and lymphatic system disorders | 13/43 |
| DiarrhoeaGastrointestinal disorders | 10/43 |
| NasopharyngitisInfections and infestations | 8/43 |
| FatigueGeneral disorders | 8/43 |
Intent-To-Treat (ITT) population: all participants who received at least one dose of study medication.
| Age, Continuous(years) | Rituximab, Fludarabine, Cyclophosphamide |
|---|---|
| Mean | 61.0 ± 10.1 |
| Sex: Female, Male(Participants) | Rituximab, Fludarabine, Cyclophosphamide |
|---|---|
| Female | 14 |
| Male | 29 |
Ran from Oct 2005 to primary completion in Sep 2012, 83 months.
Results were first posted in Sep 2014, 1 year 11 months after primary completion.
Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's 83 months is above that.
Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rituximab
Leukemia, Lymphocytic, Chronic, B-Cell →